NUCLEAR medicine is one the most important fields to inspect and treat tumors by radiation or by introducing labeled radiopharmaceuticals, which are in the spot of our interest. In this study, the authors investigated the possibility of using mebeverine as a solid tumor marker. Mebeverine was labeled with Technetium (^99mTc-Meb) reaching a radiochemical yield (RCY) of 97% via a reduction reaction using SnCl₂. The tracer showed a high stability in the serum for 12 hours which is essential to avoid any undesired accumulations in the non-target organs. Its bioevaluation in normal and induced tumored mice was performed to identify the capability of the use of the tracer for the diagnosis of solid tumors. The uptake by the tumor was 14.2% after 30 min of injection and increased to 18.5%, viewing a decline after 3 hours, this could be attributed to that washout to the tumored muscle extravasation. Tumored /Non-Tumored (T/NT) ratio was applied, the ratio reached 3.14 which shows the selectivity of ^99mTc-Meb to the solid tumor induced in the right thigh.